NervGen Pharma to Present at the Unite 2 Fight Paralysis 19th Annual Science & Advocacy Symposium Focused on Spinal Cord Injury
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company, announced that its Chief Medical Officer, Daniel Mikol, MD, Ph.D., will present at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science & Advocacy Symposium on September 27-28, 2024, in Atlanta, Georgia.
Dr. Mikol's presentation, titled 'Clinical Trials in Spinal Cord Injury ... Lost in Translation?', will be delivered during Session 6 on Saturday, September 28, from 11:00 a.m. to 11:20 a.m. EDT at the Atlanta Marriott Marquis. He will discuss the challenges of translating results from animal models to human clinical trials for spinal cord injury (SCI).
The U2FP Symposium is a significant event that gathers research scientists, clinicians, investors, SCI survivors, and family members to promote knowledge, collaboration, and empowerment for stakeholders dedicated to finding a cure for SCI.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), un'azienda biotech in fase clinica, ha annunciato che il suo Chief Medical Officer, Daniel Mikol, MD, Ph.D., presenterà al 19° Symposium Annuale di Scienza e Advocacy di Unite 2 Fight Paralysis (U2FP) che si terrà dal 27 al 28 settembre 2024, ad Atlanta, Georgia.
La presentazione del Dott. Mikol, intitolata 'Clinical Trials in Spinal Cord Injury ... Lost in Translation?', si svolgerà durante la Sessione 6 sabato 28 settembre, dalle 11:00 alle 11:20 EDT presso l'Atlanta Marriott Marquis. Discuterà le sfide della traduzione dei risultati dai modelli animali agli studi clinici umani per le lesioni del midollo spinale (SCI).
Il Symposium U2FP è un evento significativo che riunisce scienziati di ricerca, clinici, investitori, sopravvissuti a SCI e membri delle famiglie per promuovere conoscenza, collaborazione e empowerment per gli stakeholder dedicati a trovare una cura per le SCI.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), una empresa biofarmacéutica en etapa clínica, anunció que su Director Médico, Daniel Mikol, MD, Ph.D., presentará en el 19º Simposio Anual de Ciencia y Defensa de Unite 2 Fight Paralysis (U2FP) que se llevará a cabo del 27 al 28 de septiembre de 2024, en Atlanta, Georgia.
La presentación del Dr. Mikol, titulada 'Clinical Trials in Spinal Cord Injury ... Lost in Translation?', se realizará durante la Sesión 6 el sábado 28 de septiembre, de 11:00 a.m. a 11:20 a.m. EDT en el Atlanta Marriott Marquis. Hablará sobre los desafíos de traducir los resultados de modelos animales a ensayos clínicos humanos para lesiones de la médula espinal (SCI).
El Simposio U2FP es un evento significativo que reúne a científicos de investigación, clínicos, inversores, sobrevivientes de SCI y miembros de la familia para promover el conocimiento, la colaboración y el empoderamiento de los interesados dedicados a encontrar una cura para la SCI.
너브젠 파마 코프(NervGen Pharma Corp.) (TSXV: NGEN) (OTCQB: NGENF), 임상 단계의 생명공학 회사가 발표했습니다. 의학 책임자(Daniel Mikol, MD, Ph.D.)가 2024년 9월 27일부터 28일까지 조지아주 애틀랜타에서 열리는 제19회 유나이트 2 파라리시스(United 2 Fight Paralysis, U2FP) 연례 과학 및 옹호 심포지엄에 참가합니다.
미콜 박사의 발표 제목은 '척수 손상에서의 임상 시험 ... 번역에서 잃어버린 것들?'이며, 9월 28일 토요일, EDT 기준 오전 11시부터 11시 20분까지 애틀랜타 메리어트 마퀴스에서 진행됩니다. 그는 척수 손상(SCI)에 대한 동물 모델에서 인간 임상 시험으로의 결과를 번역하는 데 있는 어려움에 대해 논의할 것입니다.
U2FP 심포지엄은 연구 과학자, 클리닉 전문가, 투자자, SCI 생존자 및 가족을 모아 지식, 협력 및 SCI 치료를 찾기 위해 헌신하는 이해 관계자들에게 힘을 실어주는 중요한 행사입니다.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), une société biopharmaceutique en phase clinique, a annoncé que son Directeur Médical, Daniel Mikol, MD, Ph.D., présentera au 19ème Symposium Annuel sur la Science et le Plaidoyer de Unite 2 Fight Paralysis (U2FP) qui se tiendra les 27 et 28 septembre 2024 à Atlanta, Géorgie.
La présentation du Dr Mikol, intitulée 'Essais Cliniques sur les Blessures de la Moelle Épinière ... Perdu dans la Traduction ?', aura lieu lors de la Session 6 le samedi 28 septembre, de 11h00 à 11h20 EDT au Atlanta Marriott Marquis. Il discutera des défis liés à la traduction des résultats des modèles animaux dans les essais cliniques humains pour les blessures de la moelle épinière (SCI).
Le Symposium U2FP est un événement important qui rassemble des chercheurs, cliniciens, investisseurs, survivants de SCI et membres de leur famille pour promouvoir la connaissance, la collaboration et l'autonomisation des parties prenantes dédiées à la recherche d'un remède pour le SCI.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), ein biopharmazeutisches Unternehmen in klinischer Phase, gab bekannt, dass sein Chief Medical Officer, Daniel Mikol, MD, Ph.D., auf dem 19. Jahreswissenschafts- und Advocacy-Symposium von Unite 2 Fight Paralysis (U2FP) am 27. und 28. September 2024 in Atlanta, Georgia, präsentieren wird.
Die Präsentation von Dr. Mikol mit dem Titel 'Klinische Studien bei Rückenmarksverletzungen ... Verloren in der Übersetzung?' findet während Sitzung 6 am Samstag, den 28. September, von 11:00 bis 11:20 Uhr EDT im Atlanta Marriott Marquis statt. Er wird die Herausforderungen diskutieren, die damit verbunden sind, Ergebnisse von Tiermodellen in humane klinische Studien bei Rückenmarksverletzungen (SCI) zu übersetzen.
Das U2FP-Symposium ist eine bedeutende Veranstaltung, die Forschungswissenschaftler, Kliniker, Investoren, SCI-Überlebende und Familienmitglieder zusammenbringt, um Wissen, Zusammenarbeit und Empowerment für Interessengruppen zu fördern, die sich der Suche nach einem Heilmittel für SCI widmen.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will give an oral presentation at the Unite 2 Fight Paralysis (U2FP) 19th Annual Science & Advocacy Symposium, taking place on September 27-28, 2024, in Atlanta, Georgia. Dr. Mikol will present "Clinical Trials in Spinal Cord Injury … Lost in Translation?" during Session 6 on Saturday, September 28, from 11:00 a.m. to 11:20 a.m. EDT, at the Atlanta Marriott Marquis.
"There are many challenges in translating results from animal models of spinal cord injury (SCI) to clinical trials of humans with SCI," said Dr Mikol. "I am honored to have been invited to speak at this meeting and look forward to highlighting some of these challenges as well as considerations for how clinical translation might be more successful."
The U2FP 19th Annual Science & Advocacy Symposium is a pivotal event that brings research scientists, clinicians, investors, SCI survivors and family members together to foster knowledge, collaboration and power for all the stakeholders committed to achieving a cure for SCI.
About NVG-291
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular wedge domain of the receptor type protein tyrosine phosphatase sigma (PTPσ). NVG-291-R, a rodent analog of NVG-291, has been shown to promote nervous system repair and functional recovery in animal models of spinal cord injury (acute and chronic intervention), peripheral nerve injury, multiple sclerosis and stroke, through enhanced plasticity, axonal regeneration, and remyelination. NVG-291 has received Fast Track Designation in spinal cord injury from the U.S. Food and Drug Administration.
About Phase 1b/2a Trial
The double-blind, placebo-controlled proof-of-concept trial (NCT05965700) will evaluate the efficacy of NVG-291 in two separate cohorts of individuals with cervical spinal cord injury: chronic (1-10 years post-injury) and subacute (those with a more recent injury), given demonstrated efficacy in preclinical models of both chronic and acute spinal cord injury. The trial is designed to evaluate efficacy of a fixed dose of NVG-291 using multiple clinical outcome measures as well as objective electrophysiological and MRI imaging measures and blood biomarkers that together will provide comprehensive information about the extent of recovery of function, with a focus on improvements in motor function. Specifically, the primary objective is to assess the change in corticospinal connectivity of defined upper and lower extremity muscle groups following treatment based on changes in motor evoked potential amplitudes. Secondary objectives are to evaluate changes in a number of clinical outcome assessments focusing on motor function, upper extremity dexterity and grasping and mobility, as well as changes in additional electrophysiological measurements. Each cohort will be evaluated independently as the data becomes available. The trial is being partially funded by a grant from Wings for Life, which is being provided in several milestone-based payments that will offset a portion of the direct costs of this clinical trial.
About NervGen
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself in the settings of traumatic injury and disease. NervGen's lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company's initial target indication, spinal cord injury. The company has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X, LinkedIn, and Facebook for the latest news on the company.
Contacts
Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com
858.717.2310
646.942.5604
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation. Such forward-looking statements and information herein include, but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the subject matter to be presented at the upcoming conference; the objectives, timing and study design of the clinical development of NVG-291 in spinal cord injury; the receipt of the milestone-based grant payments; the development plans and prospective target indications for NVG-300; and the creation of innovative treatments of nervous system damage due to trauma or disease.
Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, the Company has relied on various assumptions, including, but not limited to: the Company's ability to manage the effects of pandemics such as COVID-19; the accuracy of the Company's financial projections; the Company obtaining positive results in its clinical and other trials; the Company obtaining necessary regulatory approvals; and general business, market and economic conditions.
Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, the impact of pandemics such as COVID-19, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the Company's Annual Information Form, Prospectus Supplement, financial statements and Management Discussion and Analysis which can be found on SEDARplus.ca. All clinical development plans are subject to additional funding.
Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223895
FAQ
What is the focus of Daniel Mikol's presentation at the U2FP Symposium?
When and where will Daniel Mikol present at the U2FP 19th Annual Science & Advocacy Symposium?
What is the title of Daniel Mikol's presentation at the U2FP Symposium?
What is the significance of the U2FP 19th Annual Science & Advocacy Symposium?
What is the stock symbol for NervGen Pharma Corp.?
